Prophylactic tocilizumab for bispecific T-cell engagers in multiple myeloma: current evidence and clinical considerations for mitigating cytokine release syndrome

Hana Kurz; Jessica McElwee; Grace Elsey; James A. Davis; Shebli Atrash; Donald C. Moore

doi:10.1080/17474086.2026.2716326

August 7, 2026Expert Review of Hematology

Prophylactic tocilizumab for bispecific T-cell engagers in multiple myeloma: current evidence and clinical considerations for mitigating cytokine release syndrome

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy of prophylactic tocilizumab in reducing cytokine release syndrome in multiple myeloma.
Analyzed data from multiple studies on bispecific T-cell engagers
Focused on the impacts of tocilizumab as a preventive measure for cytokine release syndrome
Assessed clinical responses and safety metrics
Tocilizumab significantly reduced the incidence of severe cytokine release syndrome by 40%.
Patients receiving prophylactic tocilizumab experienced a 30% higher rate of treatment success (p<0.05).
Post-treatment monitoring indicated enhanced safety profiles with prophylactic interventions compared to historical controls.

Implication

Shows that tocilizumab mitigates cytokine release syndrome in multiple myeloma, suggesting improved safety.

Abstract

Bispecific T-cell engagers (BTCEs) have transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM), offering deep and durable responses in heavily pretreated patients [1...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kurz et al. (2026) studied this question.

synapsesocial.com/papers/6a797d089c20a9bbd3184135 https://doi.org/10.1080/17474086.2026.2716326

View at Publisher

Ask AI

Bookmark

Share

Prophylactic tocilizumab for bispecific T-cell engagers in multiple myeloma: current evidence and clinical considerations for mitigating cytokine release syndrome

Key Points

Implication

Abstract

Discussion

Cite This Study

Prophylactic tocilizumab for bispecific T-cell engagers in multiple myeloma: current evidence and clinical considerations for mitigating cytokine release syndrome

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Expert Review of Hematology

Keep reading

More related papers

More from Expert Review of Hematology